ARMP (43) OTLK (38) HUMA (36) MOLN (49) ⌘ Pro Terminal →

Anavex Life Sciences Corp. (AVXL) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell AVXL stock right now?

Anavex Life Sciences Corp. (AVXL) currently earns a Roarable Rating of D (Sell — SELL) with 48/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is AVXL's 12-month price target and RQD AI Jury consensus?

AVXL's 12-month base price target is $1.24 (range $0.97 to $8.34), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$1.30 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.30

Anavex Life Sciences Corp. (AVXL) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $120.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.30 (-0.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AVXL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (48/100 Composite)

🔍 WHY AVXL SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (31% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 20.8 (OVERSOLD (<32))

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$1.49-12.1% Next Q

Q2 (-2Q)

Grade C-$1.31+1.5% Next Q

Q3 (-1Q)

Grade C-$1.33-2.3% Next Q

Current

Grade D$1.30-5.6% Hist 90D α

Trajectory: C (56) → D (48)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AVXL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AVXL currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.14) and Max Pain ($1.37) forces dealer call-delta covering toward $8.34.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AVXL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AVXL Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 48%NO 52%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

20.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

1 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$1.30H: $8

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on AVXL

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (30)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (53)

17/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like AVXL

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AVXL)

✓Walkthrough of AVXL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AVXL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -61.08%📐 HORIZONTAL RANGE

2026-10-30O $1.30H $1.30L $1.18C $1.30VOL 1.20M

RES: $3.79SUP: $1.01SMA50: $2.14SMA200: $3.09

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AVXL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AVXL Butterfly Map → + Track AVXL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AVXL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AVXL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AVXL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AVXL)

Health Care Rank #383 of 1016 ⚔️ ARMP vs AVXL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AVXL vs. ARMP, OTLK, HUMA, MOLN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Anavex Life Sciences Corp. (AVXL) ranks #383 by composite RQD confidence (48/100, grade D) and #634 by equity capitalization ($120.5M). Within this direct 5-issuer industry benchmark cohort, AVXL leads on earnings valuation at N/A trailing P/E, while AVXL leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MOLN currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with AVXL at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AVXL ACTIVE Anavex Life Sciences Corp.	D	48/100	—	—	-35.0%	0.00%	$120.5M	Benchmark Subject
ARMP Armata Pharmaceuticals Inc.	D-	43/100	—	—	-35.0%	-1.22%	$120.8M	/armp-vs-avxl →
OTLK Outlook Therapeutics Inc.	D-	38/100	—	4.0%	-35.0%	-9.43%	$120.1M	/otlk-vs-avxl →
HUMA Humacyte Inc.	D-	36/100	—	-30.0%	-35.0%	-0.06%	$130.5M	/huma-vs-avxl →
MOLN Molecular Partners AG	D	49/100	—	—	—	-4.88%	$132.4M	/moln-vs-avxl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001314052

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Anavex Life Sciences Corp. (AVXL) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$46.4M, operating cash flow of -$39.0M, and free cash flow of -$39.0M (-26.7% YoY). On the balance sheet, AVXL closed FY2025 with $133.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$0	-$46.4M	-$39.0M	-$39.0M	$133.0M	—
FY2024 (FY)	2024-09-30	$0	-$43.0M	-$30.8M	-$30.8M	$124.0M	—
FY2023 (FY)	2023-09-30	$0	-$47.5M	-$27.8M	-$27.8M	—	—

3. AVXL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AVXL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Anavex Life Sciences Corp. (NASDAQ: AVXL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $1.30 (0.00% 1D, market cap $120.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AVXL ranks #383 in composite RQD confidence.

How does AVXL compare to ARMP and OTLK in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AVXL carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ARMP (Armata Pharmaceuticals Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $120.8M) and OTLK (Outlook Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $120.1M). Among the 5-stock peer group, AVXL leads on earnings multiple (N/A) while AVXL leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AVXL?

Per AVXL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001314052), Anavex Life Sciences Corp. generated $0 in revenue, -$46.4M in net income, and -$39.0M in free cash flow against $133.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AVXL trading relative to its 50-day, 200-day, and 52-week technical levels?

AVXL last traded at $1.30 (0.00% on volume of 900,167 shares), positioning the stock -39.25% below its 50-day simple moving average ($2.14) and -57.93% below its 200-day simple moving average ($3.09). Across its 52-week range of $1.14 to $7.94, AVXL sits at the 2.4% percentile with a 14-day RSI of 20.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.14 to $1.46).

AVXL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell AVXL stock right now?

Anavex Life Sciences Corp. (AVXL) currently earns a Roarable Rating of D (Sell — SELL) with 48/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is AVXL's 12-month price target and RQD AI Jury consensus?

AVXL's 12-month base price target is $1.24 (range $0.97 to $8.34), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: AVXL RQD Cockpit AVXL 12M Forecast AVXL Earnings & Move AVXL Dividends & DRIP AVXL Insiders & 13F AVXL Whale Options AVXL Profit Sankey AVXL News & Why